Low maruyama index surgery for gastric cancer: Blinded reanalysis of the dutch D1-D2 trial

K. C M J Peeters, Scott A Hundahl, E. Klein Kranenbarg, H. Hartgrink, C. J H Van De Velde

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

A quantitative estimate of residual nodal disease after gastric cancer surgery, the Maruyama index of unresected disease (MI), proved to be a strong independent predictor of survival in a large U.S. adjuvant chemoradiation study in which surgical undertreatment was frequent. Data from the Dutch D1-D2 Lymphadenectomy Trial permit an opportunity to assess the prognostic value of this variable in a cohort with lower-stage disease treated with minimum D-1 lymphadenectomy and no adjuvant chemoradiation. Blinded to survival, and excluding those cases with missing information, the MI was calculated for 648 of the original 711 patients treated with curative intent. Survival was assessed by log-rank and multivariate Cox regression analysis. All patients have been followed for a minimum of 11 years. Overall Dutch trial findings were not affected by the absence of 63 cases with incomplete data. As expected, the median MI was 26, much lower than in the previous U.S. study. In contrast to the D level, MI < 5 proved to be a strong predictor of survival by both univariate and multivariate analysis. The MI was an independent predictor of both overall survival [P= 0.016; hazard ratio (HR) = 1.45; 95% confidence interval (CI) 1.07-1.95] and relapse risk (P = 0.010; HR = 1.72; 95% CI 1.14-2.60). A strong dose-response reaction with respect to the MI and survival was also observed. We conclude that in this trial low-MI surgery is associated with enhanced survival, whereas outside of certain subgroups routine D2 lymphadenectomy is not. This observation suggests that surgeons might have more of an impact on patient survival by achieving a low-MI operation than a particular D level. A compelling dose-response effect reveals that the MI is a quantitative yardstick for assessing the adequacy of lymphadenectomy in gastric cancer.

Original languageEnglish (US)
Pages (from-to)1576-1584
Number of pages9
JournalWorld Journal of Surgery
Volume29
Issue number12
DOIs
StatePublished - Dec 2005

Fingerprint

Stomach Neoplasms
Survival
Lymph Node Excision
Confidence Intervals
Multivariate Analysis
Regression Analysis
Recurrence

ASJC Scopus subject areas

  • Surgery

Cite this

Low maruyama index surgery for gastric cancer : Blinded reanalysis of the dutch D1-D2 trial. / Peeters, K. C M J; Hundahl, Scott A; Kranenbarg, E. Klein; Hartgrink, H.; Van De Velde, C. J H.

In: World Journal of Surgery, Vol. 29, No. 12, 12.2005, p. 1576-1584.

Research output: Contribution to journalArticle

Peeters, K. C M J ; Hundahl, Scott A ; Kranenbarg, E. Klein ; Hartgrink, H. ; Van De Velde, C. J H. / Low maruyama index surgery for gastric cancer : Blinded reanalysis of the dutch D1-D2 trial. In: World Journal of Surgery. 2005 ; Vol. 29, No. 12. pp. 1576-1584.
@article{fca9d68ca11b436ab1d39f479d2b37c3,
title = "Low maruyama index surgery for gastric cancer: Blinded reanalysis of the dutch D1-D2 trial",
abstract = "A quantitative estimate of residual nodal disease after gastric cancer surgery, the Maruyama index of unresected disease (MI), proved to be a strong independent predictor of survival in a large U.S. adjuvant chemoradiation study in which surgical undertreatment was frequent. Data from the Dutch D1-D2 Lymphadenectomy Trial permit an opportunity to assess the prognostic value of this variable in a cohort with lower-stage disease treated with minimum D-1 lymphadenectomy and no adjuvant chemoradiation. Blinded to survival, and excluding those cases with missing information, the MI was calculated for 648 of the original 711 patients treated with curative intent. Survival was assessed by log-rank and multivariate Cox regression analysis. All patients have been followed for a minimum of 11 years. Overall Dutch trial findings were not affected by the absence of 63 cases with incomplete data. As expected, the median MI was 26, much lower than in the previous U.S. study. In contrast to the D level, MI < 5 proved to be a strong predictor of survival by both univariate and multivariate analysis. The MI was an independent predictor of both overall survival [P= 0.016; hazard ratio (HR) = 1.45; 95{\%} confidence interval (CI) 1.07-1.95] and relapse risk (P = 0.010; HR = 1.72; 95{\%} CI 1.14-2.60). A strong dose-response reaction with respect to the MI and survival was also observed. We conclude that in this trial low-MI surgery is associated with enhanced survival, whereas outside of certain subgroups routine D2 lymphadenectomy is not. This observation suggests that surgeons might have more of an impact on patient survival by achieving a low-MI operation than a particular D level. A compelling dose-response effect reveals that the MI is a quantitative yardstick for assessing the adequacy of lymphadenectomy in gastric cancer.",
author = "Peeters, {K. C M J} and Hundahl, {Scott A} and Kranenbarg, {E. Klein} and H. Hartgrink and {Van De Velde}, {C. J H}",
year = "2005",
month = "12",
doi = "10.1007/s00268-005-7907-9",
language = "English (US)",
volume = "29",
pages = "1576--1584",
journal = "Presentations from the 9th Annual Electric Utilities Environmental Conference",
issn = "0364-2313",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Low maruyama index surgery for gastric cancer

T2 - Blinded reanalysis of the dutch D1-D2 trial

AU - Peeters, K. C M J

AU - Hundahl, Scott A

AU - Kranenbarg, E. Klein

AU - Hartgrink, H.

AU - Van De Velde, C. J H

PY - 2005/12

Y1 - 2005/12

N2 - A quantitative estimate of residual nodal disease after gastric cancer surgery, the Maruyama index of unresected disease (MI), proved to be a strong independent predictor of survival in a large U.S. adjuvant chemoradiation study in which surgical undertreatment was frequent. Data from the Dutch D1-D2 Lymphadenectomy Trial permit an opportunity to assess the prognostic value of this variable in a cohort with lower-stage disease treated with minimum D-1 lymphadenectomy and no adjuvant chemoradiation. Blinded to survival, and excluding those cases with missing information, the MI was calculated for 648 of the original 711 patients treated with curative intent. Survival was assessed by log-rank and multivariate Cox regression analysis. All patients have been followed for a minimum of 11 years. Overall Dutch trial findings were not affected by the absence of 63 cases with incomplete data. As expected, the median MI was 26, much lower than in the previous U.S. study. In contrast to the D level, MI < 5 proved to be a strong predictor of survival by both univariate and multivariate analysis. The MI was an independent predictor of both overall survival [P= 0.016; hazard ratio (HR) = 1.45; 95% confidence interval (CI) 1.07-1.95] and relapse risk (P = 0.010; HR = 1.72; 95% CI 1.14-2.60). A strong dose-response reaction with respect to the MI and survival was also observed. We conclude that in this trial low-MI surgery is associated with enhanced survival, whereas outside of certain subgroups routine D2 lymphadenectomy is not. This observation suggests that surgeons might have more of an impact on patient survival by achieving a low-MI operation than a particular D level. A compelling dose-response effect reveals that the MI is a quantitative yardstick for assessing the adequacy of lymphadenectomy in gastric cancer.

AB - A quantitative estimate of residual nodal disease after gastric cancer surgery, the Maruyama index of unresected disease (MI), proved to be a strong independent predictor of survival in a large U.S. adjuvant chemoradiation study in which surgical undertreatment was frequent. Data from the Dutch D1-D2 Lymphadenectomy Trial permit an opportunity to assess the prognostic value of this variable in a cohort with lower-stage disease treated with minimum D-1 lymphadenectomy and no adjuvant chemoradiation. Blinded to survival, and excluding those cases with missing information, the MI was calculated for 648 of the original 711 patients treated with curative intent. Survival was assessed by log-rank and multivariate Cox regression analysis. All patients have been followed for a minimum of 11 years. Overall Dutch trial findings were not affected by the absence of 63 cases with incomplete data. As expected, the median MI was 26, much lower than in the previous U.S. study. In contrast to the D level, MI < 5 proved to be a strong predictor of survival by both univariate and multivariate analysis. The MI was an independent predictor of both overall survival [P= 0.016; hazard ratio (HR) = 1.45; 95% confidence interval (CI) 1.07-1.95] and relapse risk (P = 0.010; HR = 1.72; 95% CI 1.14-2.60). A strong dose-response reaction with respect to the MI and survival was also observed. We conclude that in this trial low-MI surgery is associated with enhanced survival, whereas outside of certain subgroups routine D2 lymphadenectomy is not. This observation suggests that surgeons might have more of an impact on patient survival by achieving a low-MI operation than a particular D level. A compelling dose-response effect reveals that the MI is a quantitative yardstick for assessing the adequacy of lymphadenectomy in gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=19644374382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19644374382&partnerID=8YFLogxK

U2 - 10.1007/s00268-005-7907-9

DO - 10.1007/s00268-005-7907-9

M3 - Article

C2 - 16317484

AN - SCOPUS:19644374382

VL - 29

SP - 1576

EP - 1584

JO - Presentations from the 9th Annual Electric Utilities Environmental Conference

JF - Presentations from the 9th Annual Electric Utilities Environmental Conference

SN - 0364-2313

IS - 12

ER -